<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer</title>
				<funder ref="#_sE5Kb7B">
					<orgName type="full">Research Foundation for Talents of Yijishan Hospital of Wannan Medical College</orgName>
				</funder>
				<funder ref="#_KS6kqbw">
					<orgName type="full">Science and Technology Commission of 396 Huaian Municipality, Jiangsu, China</orgName>
				</funder>
				<funder ref="#_TdCeTzv">
					<orgName type="full">Foundation for High-level Talent of Provincial Public Medical and Health Institutions</orgName>
				</funder>
				<funder ref="#_EEKhRvb">
					<orgName type="full">National Natural Science Foundation of China</orgName>
				</funder>
				<funder ref="#_KZGW8f7">
					<orgName type="full">Natural Science Research Project of Anhui Educational Committee</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Rui</forename><surname>Sha</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Thyroid and Breast Surgery</orgName>
								<orgName type="institution" key="instit1">The First Affiliated Hospital of Wannan Medical College</orgName>
								<orgName type="institution" key="instit2">Yijishan Hospital of Wannan Medical College)</orgName>
								<address>
									<addrLine>2 Zheshan West Road</addrLine>
									<postCode>241001</postCode>
									<settlement>Wuhu, Anhui</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Xinrui</forename><surname>Dong</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Breast Surgery</orgName>
								<orgName type="institution">The First Affiliated Hospital With Nanjing Medical University</orgName>
								<address>
									<addrLine>300 Guangzhou Road</addrLine>
									<postCode>210029</postCode>
									<settlement>Nanjing, Jiangsu</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Shanshan</forename><surname>Yan</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Center for Medical Ultrasound</orgName>
								<orgName type="institution" key="instit1">Suzhou Municipal Hospital</orgName>
								<orgName type="institution" key="instit2">Nanjing Medical University Affiliated Suzhou Hospital</orgName>
								<address>
									<postCode>215000</postCode>
									<settlement>Suzhou, Jiangsu</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Huijuan</forename><surname>Dai</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">School of Medicine</orgName>
								<orgName type="institution" key="instit1">Renji Hospital</orgName>
								<orgName type="institution" key="instit2">Shanghai Jiaotong University</orgName>
								<address>
									<addrLine>1630 Dongfang Road</addrLine>
									<postCode>200127</postCode>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Aijun</forename><surname>Sun</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Thyroid and Breast Oncological Surgery</orgName>
								<orgName type="institution">Xuzhou Medical College Affiliated Huaian Hospital</orgName>
								<address>
									<addrLine>62 Huaihai South Road</addrLine>
									<postCode>223001</postCode>
									<settlement>Huaian, Jiangsu</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Liuxia</forename><surname>You</surname></persName>
							<email>youliuxia@126.com</email>
							<affiliation key="aff5">
								<orgName type="department">Department of Clinical Laboratory</orgName>
								<orgName type="institution">The Second Affiliated Hospital of Fujian Medical University</orgName>
								<address>
									<postCode>362000</postCode>
									<settlement>Quanzhou, Fujian</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Zongjin</forename><surname>Guo</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Interventional Radiology</orgName>
								<orgName type="institution">The University of HongKong-Shenzhen Hospital</orgName>
								<address>
									<postCode>518053</postCode>
									<settlement>Shenzhen</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">4116295A047523871399F7CD1AEA1FAB</idno>
					<idno type="DOI">10.1038/s41598-024-52638-8</idno>
					<note type="submission">Received: 25 June 2023; Accepted: 22 January 2024 Additional information</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2024-05-25T07:17+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Breast cancer is the most common diagnosed cancer, the HER2-positive subtype account for 15% of all breast cancer. HER2-targeted therapy is the mainstay treatment for HER2-positive breast cancer. Cuproptosis is a novel form of programmed cell death, and is caused by mitochondrial lipoylation and destabilization of iron-sulfur proteins triggered by copper, which was considered as a key player in various biological processes. However, the roles of cuproptosis-related genes in HER2-positive breast cancer remain largely unknown. In the present study, we constructed a prognostic prediction model of HER2-positive breast cancer patients using TCGA database. Dysregulated genes for cells resistant to HER2-targeted therapy were analyzed in the GEO dataset. KEGG pathway, GO enrichment and GSEA was performed respectively. The immune landscape of DLAT was analyzed by CIBERSORT algorithm and TIDE algorithm. HER2-positive breast cancer patients with high CRGs risk score showed shorter OS. DLAT was downregulated and correlated with better survival of HER2-positive breast cancer patients (HR = 3.30, p = 0.022). High expressed DLAT was associated with resistant to HER2-targeted therapy. Knocking down DLAT with siRNA increased sensitivity of breast cancer to trastuzumab. KEGG pathway and GO enrichment of DEGs indicated that DLAT participates in various pathways correlated with organelle fission, chromosome segregation, nuclear division, hormone-mediated signaling pathway, regulation of intracellular estrogen receptor signaling pathway, condensed chromosome and PPAR signaling pathway. There was a negative correlation between TIDE and DLAT expression (r = -0.292, p &lt; 0.001), which means high DLAT expression is an indicator of sensitivity to immunotherapy. In conclusion, our study constructed a four CRGs signature prognostic prediction model and identified DLAT as an independent prognostic factor and associated with resistant to HER2-targeted therapy for HER2-positive breast cancer patients.</p><p>Breast cancer (BC) has become the most frequently diagnosed cancer, and it is also the leading cause of cancerrelated death in women worldwide 1,2 . BC can be divided into four conventional subtypes, Luminal A, Luminal B, human epidermal growth factor 2 (HER2) positive and triple negative breast cancer (TNBC) 3 . Endocrine therapy is used for individuals with hormone receptor positive disease, chemotherapy is the primary treatment option for TNBC, and HER2-targeted therapy is utilized for patients whose tumors overexpress HER2 4,5 . About 15% of patients developed HER2-positive BC, which was characterized by a high recurrence rates, aggressive phenotype, and poor survival outcomes <ref type="bibr" target="#b6">6,</ref><ref type="bibr" target="#b7">7</ref> . The monoclonal antibody trastuzumab significantly</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Expression determination and survival assessment of cuproptosis-related genes in HER2-positive BC</head><p>The workflow of the study design was presented in Fig. <ref type="figure" target="#fig_0">1</ref>. In this study, we identified 14 genes related to cuproptosis according to the literature <ref type="bibr" target="#b31">30</ref> . The expression level of the 14 genes in HER2-positive BC were determined by the TCGA database. As shown in Fig. <ref type="figure" target="#fig_1">2A</ref>, nine genes including DLAT, DLD, GLS, LIPT1, MTF1, PDHA1, PDHB, SLC25A3 and SLC31A2 were significantly downregulated, but the other 3 genes including ATOX1, CDKN2A and SLC31A1 were significantly upregulated in HER2-positive BC compared with normal tissues. For FDX1 and LIAS, however, there had no statistical difference between HER2-positive BC and normal breast tissues. Subsequently, the prognostic values of the 14 genes were evaluated in HER2-positive BC patients. The univariate Cox hazard model suggested a higher risk of death in the high expression of DLAT (HR = 3.30, p = 0.022) and SLC25A3 (HR = 2.90, p = 0.039) group (Fig. <ref type="figure" target="#fig_1">2B</ref>). The cumulative OS curves provided a visualization of the prognosis with different DLAT and SLC25A3 expression (Fig. <ref type="figure" target="#fig_1">2C</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The prediction model for HER2-positive BC</head><p>Given that CRGs had distinct expression between normal breast tissues and HER2-positive BC, and part of these genes had predictive value for the prognosis of HER2-positive BC patients. We attempted to construct the prognostic gene set for HER2-positive BC using the LASSO method. The prognostic model was established using the 14 cuproptosis related genes in HER2-positive BC patients (Fig. <ref type="figure" target="#fig_2">3A,</ref><ref type="figure">B</ref>). The risk score = (0.1843) * DLAT + (-0.4056) * SLC31A2 + (0.7899) * SLC25A3 + (0.4987) * ATOX1. The risk score, survival status and expression of patients with HER2-positive BC were shown in Fig. <ref type="figure" target="#fig_2">3C</ref>. The further OS curve analysis showed that patients in the low-risk group had a lower risk of death and longer survival time (HR = 0.31, p = 0.026, Fig. <ref type="figure" target="#fig_2">3D</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DLAT is the potential gene resistant to HER2-targeted therapy</head><p>To identify whether the CRGs have the predictive value for resistance to HER2-targeted therapy, we first analyzed the GEO dataset, GSE121105 <ref type="bibr" target="#b32">31</ref> . Dysregulated genes for cells resistant to trastuzumab or trastuzumab + pertuzumab in combination were showed in Fig. <ref type="figure" target="#fig_3">4A,</ref><ref type="figure">B</ref>, respectively. Compared with the 14 cuproptosis related genes, only 4 genes showed differently expression in all 3 datasets (Fig. <ref type="figure" target="#fig_3">4C</ref>). Further analysis revealed that DLAT was the only gene included both in CRG model genes and resistant genes (Fig. <ref type="figure" target="#fig_3">4D</ref>). RT-qPCR found that DLAT expression was significantly down-regulated after transfected with siRNA targeting DLAT (Fig. <ref type="figure" target="#fig_3">4E</ref>). MTT assay revealed that DLAT silencing sensitized the SKBR-3 cell to trastuzumab (Fig. <ref type="figure" target="#fig_3">4F</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The relationship between DLAT expression and genetic characteristic of BC patients</head><p>The genetic characteristic of DLAT was identified. The somatic mutation rate of DLAT was 0.2% (Fig. <ref type="figure" target="#fig_4">5A</ref>). The relationship between DLAT and MMR related genes was showed in Fig. <ref type="figure" target="#fig_4">5B</ref>, and DLAT has significant correlation with EPCAM, PMS2, MSH6, MSH2 and MLH1. DLAT also had significant correlation with TMB score (r = 0.148, p = 0.049), MSI score (r = -0.203, p = 0.006) and stemness score (r = 0.299, p &lt; 0.001) (Fig. <ref type="figure" target="#fig_4">5C</ref>). By using the ssGESA method, we identified DLAT had positive correlation with DNA replication (r = 0.161, p = 0.032) and tumor proliferation (r = 0.204, p = 0.007), however, DLAT had negative correlation with angiogenesis (r = -0.197, p = 0.009) (Fig. <ref type="figure" target="#fig_4">5D</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The relationship between DLAT expression and clinical characteristic of BC patients</head><p>We analyzed the association between prognosis and DLAT expression in BC patients, however, there had no difference of OS between high or low DLAT expression patients (HR = 1.35, p = 0.08, Fig. <ref type="figure" target="#fig_5">6A</ref>). To visualize the attributes of individual patients and display any correlations with survival, we constructed the alluvial diagram (Fig. <ref type="figure" target="#fig_5">6B</ref>). The expression level of DLAT in different BC subtype according the PM50 was showed in Fig. <ref type="figure" target="#fig_5">6C</ref>, the DLAT had lower expression in Luminal A than Luminal B (p &lt; 0.001), HER2-positive (p &lt; 0.05) and Basal subtype (p &lt; 0.001), while there had no significant difference among Luminal B, HER2-positive and Basal subtype. DLAT had higher expression in T4 than T1&amp;T2&amp;T3 subtype (p &lt; 0.05, Fig. <ref type="figure" target="#fig_5">6D</ref>) and higher expression in pre-menopause than post-menopause patients (p &lt; 0.05, Fig. <ref type="figure" target="#fig_5">6E</ref>). DLAT also had higher expression in ER negative (p &lt; 0.001) and PR negative patients (p &lt; 0.01), however, there had no difference between HER2-negative and HER2-positive patients (Fig. <ref type="figure" target="#fig_5">6F</ref>). In the KM-plotter database, patients in the DLAT low expression group (HR = 1.36, p = 0.031) had significantly longer RFS than patients in the high expression group (Fig. <ref type="figure" target="#fig_5">6G</ref>). In the TNM-plotter database, the expression of DLAT had significantly difference between HER2-positive BC and  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GO, KEGG and GESA analysis for DLAT</head><p>To further investigate the potential role of DLAT for HER2-positive BC, we divided the HER2-positive BC patients into two groups according to the DLAT expression, namely, DLAT high group and DLAT low group. The upregulated and downregulated genes between the two groups were showed in Fig. <ref type="figure" target="#fig_6">7A</ref>, under the condition of given threshold of FDR &lt; 0.05 and fold change &gt; 1. KEGG pathway and GO enrichment of DEGs indicated that DLAT participates in various pathways correlate with organelle fission (GO:0048285), chromosome segregation (GO:0007059), nuclear division (GO:0000280), hormone-mediated signaling pathway (GO:0009755), regulation of intracellular estrogen receptor signaling pathway (GO:0033146), condensed chromosome (GO:0000793) and PPAR signaling pathway (hsa03320) (Fig. <ref type="figure" target="#fig_6">7B,</ref><ref type="figure">C</ref>). By performing GSEA, we further verified the potential roles of DLAT associated molecules in the regulation of cell cycle checkpoints, class I MHC mediated antigen processing presentation, DNA repair, interferon signaling and organelle biogenesis and maintenance (Fig. <ref type="figure" target="#fig_6">7D</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The immune landscape for DLAT</head><p>We used the CIBERSORT algorithm to assess the difference of immune infiltration in HER2-positive BC patients with high or low DLAT expression. There is obvious difference in the distribution of 7 out of 22 immunocytes. As compared to the DLAT low group, the infiltration of B cell naïve (p &lt; 0.01) and M2 macrophages (p &lt; 0.001) subtypes was higher, while the infiltrating of B cell memory (p &lt; 0.01), T cell CD8 + (p &lt; 0.05), T cell fh (p &lt; 0.05), Tregs (p &lt; 0.001) and Neutrophil (p &lt; 0.01) subtypes was lower in DLAT high group (Fig. <ref type="figure" target="#fig_7">8A</ref>). We analyzed the correlation between DLAT and immune checkpoint inhibitors related genes (Fig. <ref type="figure" target="#fig_7">8B</ref>). In addition, the difference in sensitivity to immunotherapy between patients in the DLAT high and low groups was further investigated using the TIDE algorithm. The TIDE algorithm is a recently developed tool for determining the efficacy of tumor immune checkpoint therapy <ref type="bibr" target="#b33">32</ref> . In the present study, we found there was a negative correlation between TIDE and DLAT expression (r = -0.292, p &lt; 0.001, Fig. <ref type="figure" target="#fig_7">8C</ref>). </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The predicted value of DLAT for HER2-low BC patients</head><p>We further established the prognostic nomogram to quantitatively predict the 1-, 2-and 3-year survival probability of HER2-low BC patients (Fig. <ref type="figure" target="#fig_8">9A</ref>). The calibration curve of the nomogram demonstrated that it could predict the survival probability relatively well (Fig. <ref type="figure" target="#fig_8">9B</ref>). Although there had no difference of OS between DLAT high and low groups for HER2-low BC patients (HR = 2.15, p = 0.24, Fig. <ref type="figure" target="#fig_8">9C</ref>). However, the HR+, DLAT low patients had longer OS than HR-, DLAT high patients (HR = 8.61, p = 0.032, Fig. <ref type="figure" target="#fig_8">9D</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>Cuproptosis is a newly defined RCD, which occurs via direct binding of copper to lipoylated components of the tricarboxylic acid (TCA) cycle and this results in lipoylated protein aggregation and subsequent iron-sulfur cluster protein loss leading to proteotoxic stress and ultimately cell death <ref type="bibr" target="#b20">19</ref> . In this study, we identified a novel The prognostic model for HER2-positive BC was established according to the LASSO method. Four CRGs, named ATOX1, DLAT, SLC31A2 and SLC25A3, were included in this prognostic model. DLAT gene was the E2 core component of the pyruvate dehydrogenase (PDH) mitochondrial enzyme complex, which encoding dihydrolipoamide acetyltransferase. Dihydrolipoamide acetyltransferase accepts acetyl groups and transfers them to coenzyme A <ref type="bibr" target="#b34">33,</ref><ref type="bibr" target="#b35">34</ref> . DLAT plays an important role in glucose metabolism and TCA cycle <ref type="bibr" target="#b20">19,</ref><ref type="bibr" target="#b36">35</ref> . Goh et al. found that DLAT had higher expression in eleven gastric cancer cells lines compared with non-cancer gastric epithelial cell line HFE145, and pyruvate level was increased when DLAT knockdown with siRNA <ref type="bibr" target="#b37">36</ref> . Another research found that DLAT expression have positive relationship with PD-L1 in a clinical hepatocellular carcinoma (HCC) cohort, and DLAT was upregulated and correlated with poor prognosis <ref type="bibr" target="#b38">37</ref> . Zhou et al. found that in the HCC cells, the proliferation and invasion ability was decreased once DLAT was knockdown, and the PI3K/Akt or Wnt/β-catenin signaling pathways were also significantly inhibited <ref type="bibr" target="#b39">38</ref> . In our study, however, DLAT was downregulated in HER2positive BC patients compared with normal tissues. Patients in the low DLAT expression group had significantly longer OS than patients in the high expression group. The negative correlation between DLAT expression and  neutrophils, macrophages and dendritic cells was found in the HCC cells <ref type="bibr" target="#b39">38</ref> . The GSEA verified the potential roles of DLAT associated molecules in the regulation of cell cycle checkpoints, class I MHC mediated antigen processing presentation, DNA repair, interferon signaling and organelle biogenesis and maintenance. DLAT may play distinct roles between HCC and HER2-positive BC.</p><p>Several potential mechanisms, such as reduced drug binding to HER2, constitutive activation of HER2 parallel or downstream signaling pathways, metabolic reprogramming or reduced immune system activation, have been identified as primary/secondary resistance to anti-HER2 agents <ref type="bibr" target="#b15">14</ref> . Trastuzumab can bind with HER2 extracellular domain IV, which can further prevent the formation of HER2-HER2 homodimers and HER2-HER3 heterodimers <ref type="bibr" target="#b40">39</ref> , this also leads to the inhibition of HER2 ectodomain shedding and prevent the expression of the p95-HER2 isoform <ref type="bibr" target="#b41">40</ref> . The additional mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Trastuzumab was recognized by Fc receptors of the innate immune system cells, including natural killer cells, antigen presenting cells and effector immune cells, once it bound to HER2 on cancer cell membranes, and this reduced the bounding of trastuzumab with cancer cell <ref type="bibr" target="#b42">41,</ref><ref type="bibr" target="#b43">42</ref> . In our study, we found that DLAT high expressed HER2-positive BC patients have shorter OS and associated with resistance to trastuzumab and trastuzumab + pertuzumab. We identified DLAT had positive correlation with DNA replication and tumor proliferation and DLAT also had higher expression in T4 stage than T1&amp;T2&amp;T3 stage. All the evidence suggests that HER2-positive BC patients with high DLAT expression have a higher degree of malignancy and get limited benefits from HER2-targeted therapy. In our vitro experiment, knocking down of DLAT with siRNA significantly improved the treatment effect of trastuzumab. In addition, we found that high expressed DLAT had lower TIDE score, which means it is sensitive to immunotherapy. Immunotherapy has changed the treatment of several cancer types, and it has already been approved as a standard of care for patients with TNBC <ref type="bibr" target="#b44">43,</ref><ref type="bibr" target="#b45">44</ref> . Immunotherapy for HER2-positive BC have been an interesting field and it is currently under clinical investigation. Based on the high TMB and high levels of tumor-infiltrating lymphocytes (TILs) of HER2-positive BC, investigating of immunotherapy for HER2-positive BC is feasible <ref type="bibr" target="#b46">45,</ref><ref type="bibr" target="#b47">46</ref> . In this study, we found that DLAT also had significant positive correlation with TMB. DLAT high expressed HER2-positive BC patients may benefit from HER2-targeted therapy combined with immunotherapy.</p><p>Disruption of mitochondrial activity leading to physiological imbalances and metabolic shifts in the cell, which contribute to cancer progression. One of the most important reasons is mutations in TCA cycle enzymes <ref type="bibr" target="#b48">47,</ref><ref type="bibr" target="#b49">48</ref> . However, as part of the TCA cycle enzymes, the somatic mutation rate of DLAT was 0.2% according to this study. The typical PDH deficiency patients were caused by E1α mutations, however, two PDH deficiency patients with DLAT mutation reported by Head et al. were less severely and both have survived well into childhood <ref type="bibr" target="#b50">49</ref> . Shatokhina et al. demonstrated that DLAT was down regulated after the control U87 glioma cells were exposed under glutamine deprivation <ref type="bibr" target="#b51">50</ref> . In our study, the expression level of DLAT had no difference between HER2-negative and HER2-positive patients. Nevertheless, it was still ambiguous whether DLAT was aberrant regulated in HER2-positive BC patients under some specific conditions. TCA cycle genes including IDH2, SUCLA2, SDHB, SDHD were downregulated after co-expression of HER2 and mucin 1 cytoplasmic domain (MUC1-CD). Interestingly, MUC1-CD induced reduction in TCA cycle genes was found to be significantly associated with poor survivals in patients with HER2-positive BC <ref type="bibr" target="#b52">51</ref> . Chang et al. demonstrated that in trastuzumab resistant gastric cancer cell lines (NCI N87R and MKN45R), the activity of GATA binding protein 6 (GATA6) was enhanced prominently. In GATA6 knockout cell lines, the sensitivity to trastuzumab was improved and the mitochondrial function was inhibited <ref type="bibr" target="#b53">52</ref> . As DLAT plays an important role in glucose metabolism and TCA cycle, it also acted as a CRGs. In our study, KEGG pathway and GO enrichment of DEGs indicated that DLAT participates in various pathways correlate with organelle fission, chromosome segregation, nuclear division, hormone-mediated signaling pathway, regulation of intracellular estrogen receptor signaling pathway, condensed chromosome and PPAR signaling pathway. Despite the fact that the expression of DLAT had no difference between HER2-negative and HER2-positive BC patients, the exact function of DLAT in HER2-positive BC need further investigation.</p><p>In summary, we identified a novel prognostic model consisting of four CRGs for HER2-positive BC patients. In addition, DLAT was further confirmed to be downregulated and correlated with better survival of HER2positive BC patients. High expressed DLAT related to resistance to HER2-targeted therapy and sensitivity to immunotherapy. However, this study also had some limitations. Firstly, the 14 CRGs were selected from the literature and there may exist some other genes related with cuproptosis, those results we got just applicable at the present stage. Secondly, we did not explore the detailed function of the four CRGs, especially DLAT, in HER2positive BC. Furthermore, it is unclear how DLAT affects anti-tumor immunity in HER2-positive BC patients. </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc>Figure 1. Workflow of the current study. All of the TCGA BRCA data used in this study are HER2-positive type, unless otherwise stated.</figDesc><graphic coords="3,74.29,50.50,479.88,454.92" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc>Figure 2. Expression difference and survival analysis of CRGs in HER2-positive breast cancer. (A) Expression difference of 14 CRGs in HER2-positive breast cancer and normal breast tissues. *p &lt; 0.05; ***p &lt; 0.001; ns, no significance. (B) The forest plot of univariate COX hazard model of the 14 CRGs. *p &lt; 0.05. (C) The OS curves of DLAT and SLC25A3 in patients with HER2-positive breast cancer in the low and high expression group.</figDesc><graphic coords="4,155.91,50.50,369.48,564.96" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 .</head><label>3</label><figDesc>Figure 3. Construction of the cuproptosis-related prognostic signature. (A) LASSO regression analysis of 14 prognostic CRGs. (B) Cross validation method to select optimal genes. (C) Rank dot, scatter plots and heat map of the model gene expression. (D) Kaplan-Meier analyses of the OS between the high risk and low risk group.</figDesc><graphic coords="5,74.29,50.50,479.88,360.36" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 .</head><label>4</label><figDesc>Figure 4. Selection for the CRGs that related to HER2-targeted therapy. (A) Dysregulated genes for cells resistant to trastuzumab in GSE121105. (B) Dysregulated genes for cells resistant to trastuzumab + pertuzumab in GSE121105. (C) Venn diagram of trastuzumab resistance, trastuzumab + pertuzumab resistance and CRGs. (D) Venn diagram of resistant genes and CRG model genes. (E) The relative expression of DLAT after transfected with si-DLAT. ***p &lt; 0.001. (F) Effect of trastuzumab on growth inhibition in SKBR-3 breast cancer cells transfected with si-DLAT. *p &lt; 0.05; **p &lt; 0.01; ***p &lt; 0.001.</figDesc><graphic coords="6,155.91,50.50,338.16,476.40" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 5 .</head><label>5</label><figDesc>Figure 5. The genetic characteristic of DLAT. (A) The somatic mutation of DLAT. (B) The relationship between DLAT and MMR related genes. (C) The relationship between DLAT and TMB, TSI, stemness score. (D) The relationship between DLAT and DNA replication, tumor proliferation, angiogenesis.</figDesc><graphic coords="7,74.29,50.50,479.88,452.52" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6. The clinical characteristic of DLAT. (A) The OS curves of breast cancer patients with DLAT low and high expression group. (B) The alluvial diagram of DLAT with clinical characteristic. (C) DLAT expression in different PM50 subtype. *p &lt; 0.05; ***p &lt; 0.001; ns, no significance. (D) DLAT expression in different T stage. *p &lt; 0.05. (E) DLAT expression in different menopause status. *p &lt; 0.05. (F) DLAT expression in different ER status, PR status and HER2 status. **p &lt; 0.01; ***p &lt; 0.001; ns No significance. (G) The RFS curves of HER2positive BC patients with DLAT low and high expression group. (H) DLAT expression between normal breast tissues and HER2-positive BC tissues. (I) DLAT expression among normal breast tissues, HER2-positive BC tissues and metastatic tissues.</figDesc><graphic coords="8,131.17,50.50,423.00,539.16" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 7 .</head><label>7</label><figDesc>Figure 7. Functional analysis for DLAT. (A) The volcano map for DEGs in DLAT high or low group. (B) The GO enrichment and KEGG pathway for DEGs in DLAT high or low group. (C) The netplot of KEGG pathway of the DEGs. (D) The significantly enrichment pathway in DLAT high or low group according to the GSEA.</figDesc><graphic coords="9,74.29,50.50,479.88,394.08" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Figure 8 .</head><label>8</label><figDesc>Figure 8. The immune landscape for DLAT. (A) The infiltrating levels of immune cells in high and low DLAT expression groups in HER2-positive breast cancer patients. *p &lt; 0.05; **p &lt; 0.01; ***p &lt; 0.001. (B) The correlation between DLAT and immune checkpoint inhibitors related genes. (C) TIDE predicted response to immunotherapy.</figDesc><graphic coords="10,74.29,50.50,479.88,507.96" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head>Figure 9 .</head><label>9</label><figDesc>Figure 9. The predicted value of DLAT for HER2-low breast cancer patients. (A) The nomogram for predicting HER2-low breast cancer patients' 1-, 2-, and 3-year OS probability. (B) The 1-, 2-, and 3-year calibration curves of the nomogram. (C) The OS curves of HER2-low breast cancer patients between DLAT low and high groups. (D) The OS curves of HER2-low breast cancer patients between HR+, DLAT low and HR-, DLAT high groups.</figDesc><graphic coords="11,74.29,50.50,479.88,385.08" type="bitmap" /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p>Scientific Reports | (2024) 14:2908 | https://doi.org/10.1038/s41598-024-52638-8</p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p>Scientific Reports | (2024) 14:2908 | https://doi.org/10.1038/s41598-024-52638-8</p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>Acknowledgements</head><p>We are grateful to our lab members for valuable discussion.</p></div>
			</div>
			<div type="funding">
<div><head>Funding</head><p>The conduct of this study was sponsored and funded by <rs type="funder">National Natural Science Foundation of China</rs> (Grant Number <rs type="grantNumber">82303865</rs>) to <rs type="person">Huijuan Dai</rs>, the <rs type="funder">Research Foundation for Talents of Yijishan Hospital of Wannan Medical College</rs> (Grant Number <rs type="grantNumber">YR20220201</rs>), <rs type="funder">Natural Science Research Project of Anhui Educational Committee</rs> (Grant Number <rs type="grantNumber">2023AH051770</rs>) and <rs type="funder">Foundation for High-level Talent of Provincial Public Medical and Health Institutions</rs> (Grant Number <rs type="grantNumber">GCCRC2022013</rs>) to <rs type="person">Rui Sha</rs>, the <rs type="funder">Science and Technology Commission of 396 Huaian Municipality, Jiangsu, China</rs> (Grant Number <rs type="grantNumber">HAB202209</rs>) to <rs type="person">Aijun Sun</rs>.</p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_EEKhRvb">
					<idno type="grant-number">82303865</idno>
				</org>
				<org type="funding" xml:id="_sE5Kb7B">
					<idno type="grant-number">YR20220201</idno>
				</org>
				<org type="funding" xml:id="_KZGW8f7">
					<idno type="grant-number">2023AH051770</idno>
				</org>
				<org type="funding" xml:id="_TdCeTzv">
					<idno type="grant-number">GCCRC2022013</idno>
				</org>
				<org type="funding" xml:id="_KS6kqbw">
					<idno type="grant-number">HAB202209</idno>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data availability</head><p>Any data and R script in this study can be obtained from the corresponding author upon reasonable request. The final manuscript was read and approved by all authors. In this study, publicly available datasets were analyzed. These are available on The Cancer Genome Atlas (https:// portal. gdc. cancer. gov/) and GEO (https:// www. ncbi. nlm. nih. gov/).</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Expression analysis and survival analysis of prognostic CRGs in breast cancer</head><p>Fourteen genes related to cuproptosis were retrieved from the latest literature <ref type="bibr" target="#b31">30</ref> . The differential expression of 14 CRGs between BC and normal tissues was compared with student t-test, including ATOX1, CDKN2A, DLAT, DLD, FDX1, GLS, LIAS, LIPT1, MFT1, PDHA1, PDHB, SLC25A3, SLC31A1, and SLC31A2. Univariate Cox regression analysis was performed to find genes with prognostic value in HER2-positive BC. Survival analyses were performed and Kaplan-Meier survival curves were constructed. The boxplot, forest plot and survival plot were carried out with R packages 'ggplot2' , 'forestploter' , and 'suviminer' .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The establishment of a CRG-based model and prognostic analysis</head><p>We established an efficient prediction model using LASSO-Cox analysis according to the methods mentioned in this article <ref type="bibr" target="#b54">53</ref> . The risk score was calculated as follows: Riskscore = (0.1843) * DLAT + (-0.4056) * SLC31A2 + (0.7899) * SLC25A3 + (0.4987) * ATOX1. The coefficient index represents the risk factor, and the gene name represents the expression level of each gene. According to the median risk score, the patients were divided into high risk (risk score &gt; median) and low risk (risk score &lt; median) groups. The LASSO regression, rank dot plot, scatter plots, heat map and survival plot were carried out with R packages 'ggplot2' , 'glmnet' , and 'suviminer' .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Differential expression genes (DEGs) in trastuzumab-resistant datasets</head><p>The anti-HER2 therapy datasets were derived from GSE121105 from GEO. We used three groups in this dataset: normal HER2-positive BC cell line (BT474), Trastuzumab resistant cell line (BT474-TR1, BT474-TR2), and both Trastuzumab and Pertuzumab resistant cell line (BT-TPR1, BT-TPR2). Each group contains 3 replicates of sequencing data. The DEGs were selected using the empirical Bayesian approach <ref type="bibr" target="#b55">54</ref> . The significance criteria were set as an adjusted p value &lt; 0.001 and an absolute value of Log 2 Fold change &gt; 1.5. The volcano plot and Venn diagram were carried out with R packages 'GEOquery' , 'limma' , 'ggplot2' , and 'VennDiagram' .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The analyses of DLAT's correlation with genetic characteristics</head><p>The genetic characteristics information was obtained from TCGA. The somatic DNA mutations of DLAT were downloaded and visualized using the R packages 'maftools' . The DNA mismatch repair (MMR) was evaluated with the expression of 5 mismatching repair genes <ref type="bibr" target="#b56">55</ref> . The Tumor mutation burden (TMB) <ref type="bibr" target="#b57">56</ref> , Microsatellite instability (TSI) <ref type="bibr" target="#b58">57</ref> , and cancer stemness score <ref type="bibr" target="#b59">58</ref> were calculated with Spearman's correlation analysis. The genes related to the DNA replication, tumor proliferation and angiogenesis were picked up from the pathways mentioned in this article <ref type="bibr" target="#b60">59</ref> with R package 'GSVA' chosing parameter as method = 'ssgsea' and also analyzed by Spearman's correlation. The scatter plot was carried out with R packages 'ggstatsplot' .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The analyses of DLAT's correlation with clinical features</head><p>Based on TCGA data, the Kruskal-Wallis test was used to explore the relationships between DLAT and clinical features (ages, pTNM stages, PAM50 subtypes, menopause status, and biomarkers). The boxplot, Sankey diagram, and survival plot were carried out with R packages 'ggplot2' , 'ggalluvial' , and 'suviminer' . The KM-plotter database <ref type="bibr" target="#b61">60</ref> was used to explore the replase free survival (RFS) of HER2-positive BC with different DLAT expression. TNM plotter database <ref type="bibr" target="#b62">61</ref> were used to explore the expression of DLAT in normal breast tissues, HER2positive BC and metastatic tissues.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The functional enrichment analyses of DLAT</head><p>HER2-positive BC samples in the TCGA dataset were divided by DLAT median expression to obtain DEGs. The significance criteria were set as an adjusted p value &lt; 0.001 and an absolute value of Log 2 Fold change &gt; 1. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes Genomes (KEGG) <ref type="bibr" target="#b63">62,</ref><ref type="bibr" target="#b64">63</ref> analyses were based on the DEGs. The Gene Set Enrichment Analysis (GSEA) of DLAT was further investigated. All the functional enrichment analyses and visualization were carried out with R packages 'clusterProfiler' , 'org.Hs.eg.db' , 'msigdbr' , 'GOplot' , and 'ggplot2' .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The immunological analyses of DLAT in the HER2-positive breast cancer microenvironment</head><p>The immune landscape of DLAT was first investigated by calculating by CIBERSORT algorithm <ref type="bibr" target="#b65">64</ref> by using R package 'immunedeconv' . The immune checkpoint markers were extracted from a previous article <ref type="bibr" target="#b66">65</ref> and analyzed by Spearman's correlation. The boxplot and heatmap were carried out with R packages 'ggplot2'and 'corrplot' . The potential response to immunotherapy was predicted by the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm (http:// tide. dfci. harva rd. edu/) <ref type="bibr" target="#b33">32</ref> . The scatter plot was carried out with R packages 'ggstatsplot' .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Confirming the prognostic value of DLAT in HER2-low patients</head><p>The HER2-low patients were defined as HER2 immunohistochemistry (IHC) results as "1+" in the TCGA dataset. The multivariate Cox regression and corresponding nomogram scoring system were used to develop predictive models of 1-, 3-, and 5-year survival rates. The calibration curve was used to compare the predicted survival </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell culture</head><p>The human breast cancer cell lines SKBR-3 was obtained from the American Type Culture Collection (ATCC), and cultured in RPMI-1640 medium (Gibco, USA) supplemented with 10% fetal bovine serum (Gibco, USA) and 1% penicillin/streptomycin (Sigma-Aldrich, USA) at 37°C in a humidified incubator with 5% CO 2 .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell transfection</head><p>To knock down DLAT gene expression, small interfering RNA (siRNAs) were transfected into cell with jetPRIME (Polyplus-transfection Inc, France) according to the Manufacturer's instructions. Prior to functional studies, we characterized and optimized the knock down of DLAT using 3 different siRNA sequences (si-DLAT-1, si-DLAT-2 and si-DLAT-3) over a concentration of 10, 25, 50 and 100 nM. 50 nM of siRNA was deemed to be optimal for knock down of DLAT. In addition, si-DLAT-1 and si-DLAT-2 were more effective in silencing DLAT expression than si-DLAT-3 (data not shown). The siRNA sequences were purchased from Life Technologies (Thermo Fisher Scientific, Rockford, IL) under the following product codes targeting the respective exons: si-DLAT-1 sequence (HSS102785, targeting exon 1): 5′-UCG CAA CAG CGU GAC UAC AGG GUA -3′; si-DLAT-2 sequence (HSS102786, targeting exon 13): 5′-GGA UAA ACU GGU CCC UGC AGA UAA U-3′. Luc control siRNA #5270471 was purchased from Life Technologies, USA.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RNA extraction and RT-qPCR</head><p>Total RNA of cells was extracted using Simply P Total RNA Extraction kit (Bioer Technology, China) and subsequently reverse transcribed to complementary deoxyribonucleic acid (cDNA) using PrimerScript™ RT Master Mix (Takara, Shiga, Japan) on a SimpliAmp™ Thermal Cycler (Applied Biosystems, Massachusetts, USA) according to the manufacturer's instructions. Obtained cDNAs were quantified with a reverse transcription quantitative polymerase chain reaction (RT-qPCR) test labeled with SYBR® green (Invitrogen, California, USA) on LightCycler® 96 (Roche, Mannheim, Germany). The gene-specific primers used were as follows: DLAT forward primer, 5′-CCG CCG CTA TTA CAG TCT TCC-3′, DLAT reverse primer: 5′-CTC TGC AAT TAG GTC ACC TTCAT-3′, β-actin forward primer, 5′-CAT GTA CGT TGC TAT CCA GGC-3′; β-actin reverse primer, 5′-CTC CTT AAT GTC ACG CAC GAT-3′. Gene expression levels were normalized to β-actin expression using the 2 -ΔCT method. Each cDNA sample was triplicated in 96-microwell plates.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell growth assay</head><p>Growth inhibition was assessed using the 3-( <ref type="formula">4</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head><p>The authors declare no competing interests.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<idno type="DOI">10.1038/s41598-024-52638-8www.nature.com/scientificreports/</idno>
		<ptr target="https://doi.org/10.1038/s41598-024-52638-8www.nature.com/scientificreports/" />
	</analytic>
	<monogr>
		<title level="m">normal breast tissues (p &lt; 0.001, Fig. 6H), and it also varies among normal breast tissues, tumor tissues and metastatic tissues</title>
		<title level="s">Scientific Reports |</title>
		<imprint>
			<date type="published" when="2024">1234567890. 2024</date>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">2908</biblScope>
		</imprint>
	</monogr>
	<note>p &lt; 0.001, Fig. 6I</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</title>
		<author>
			<persName><forename type="first">H</forename><surname>Sung</surname></persName>
		</author>
		<idno type="DOI">10.3322/caac.21660</idno>
		<ptr target="https://doi.org/10.3322/caac.21660" />
	</analytic>
	<monogr>
		<title level="j">CA Cancer J. Clin</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="209" to="249" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Cancer treatment and survivorship statistics, 2022</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Miller</surname></persName>
		</author>
		<idno type="DOI">10.3322/caac.21731</idno>
		<ptr target="https://doi.org/10.3322/caac.21731" />
	</analytic>
	<monogr>
		<title level="j">CA Cancer J. Clin</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="409" to="436" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Goldhirsch</surname></persName>
		</author>
		<idno type="DOI">10.1093/annonc/mdt303</idno>
		<ptr target="https://doi.org/10.1093/annonc/mdt303" />
	</analytic>
	<monogr>
		<title level="j">Ann. Oncol. Off. J. Eur. Soc. Med. Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="2206" to="2223" />
			<date type="published" when="2013">2013. 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Breast cancer treatment: A review</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Waks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Winer</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2018.19323</idno>
		<ptr target="https://doi.org/10.1001/jama" />
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">321</biblScope>
			<biblScope unit="page">19323</biblScope>
			<date type="published" when="2018">2018. 2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Treatment of breast cancer</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Maughan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Lutterbie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Ham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am. Fam. Phys</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="1339" to="1346" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Slamon</surname></persName>
		</author>
		<idno type="DOI">10.1126/science.3798106</idno>
		<ptr target="https://doi.org/10.1126/science" />
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">235</biblScope>
			<biblScope unit="page">6</biblScope>
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Slamon</surname></persName>
		</author>
		<idno type="DOI">10.1126/science.2470152</idno>
		<ptr target="https://doi.org/10.1126/science.24701" />
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">244</biblScope>
			<biblScope unit="page">52</biblScope>
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Slamon</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejm200103153441101</idno>
		<ptr target="https://doi.org/" />
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">344</biblScope>
			<biblScope unit="page">1101</biblScope>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Piccart-Gebhart</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa052306</idno>
		<ptr target="https://doi.org/10.1056/" />
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page">6</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<idno type="DOI">10.1038/s41598-024-52638-8</idno>
		<ptr target="https://doi.org/10.1038/s41598-024-52638-8" />
		<title level="m">(1234567890) Scientific Reports |</title>
		<imprint>
			<date type="published" when="2024">2024</date>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">2908</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Romond</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa052122</idno>
		<ptr target="https://doi.org/10.1056/" />
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page">22</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Evolving standards of care and new challenges in the management of HER2positive breast cancer</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Choong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Cullen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>O'sullivan</surname></persName>
		</author>
		<idno type="DOI">10.3322/caac.21634</idno>
		<ptr target="https://doi.org/10.3322/caac.21634" />
	</analytic>
	<monogr>
		<title level="j">CA Cancer J. Clin</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="355" to="374" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">HER2-positive breast cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Loibl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gianni</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(16)32417-5</idno>
		<ptr target="https://doi.org/10.1016/s0140-6736" />
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">389</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="32417" to="32422" />
			<date type="published" when="2017">2017</date>
			<pubPlace>London, England</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">HER2-positive advanced breast cancer treatment in 2020</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Cesca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Vian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cristóvão-Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Pondé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>De Azambuja</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ctrv.2020.102033</idno>
		<ptr target="https://doi.org/10.1016/j.ctrv.2020.102033" />
	</analytic>
	<monogr>
		<title level="j">Cancer Treat. Rev</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page">102033</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives</title>
		<author>
			<persName><forename type="first">C</forename><surname>Vernieri</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.critrevonc.2019.05.001</idno>
		<idno>05. 001</idno>
		<ptr target="https://doi.org/10.1016/j.critrevonc" />
	</analytic>
	<monogr>
		<title level="j">Crit. Rev. Oncol. Hematol</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="53" to="66" />
			<date type="published" when="2019">2019. 2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Heterogeneity in breast cancer</title>
		<author>
			<persName><forename type="first">K</forename><surname>Polyak</surname></persName>
		</author>
		<idno type="DOI">10.1172/jci60534</idno>
		<ptr target="https://doi.org/10.1172/jci" />
	</analytic>
	<monogr>
		<title level="j">J. Clin. Investig</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page">534</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Breast cancer: A molecularly heterogenous disease needing subtype-specific treatments</title>
		<author>
			<persName><forename type="first">U</forename><surname>Testa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Castelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pelosi</surname></persName>
		</author>
		<idno type="DOI">10.3390/medsci8010018</idno>
		<ptr target="https://doi.org/10.3390/medsc" />
	</analytic>
	<monogr>
		<title level="j">Med. Sci</title>
		<imprint>
			<biblScope unit="volume">8010</biblScope>
			<biblScope unit="page">18</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Breast cancer stem-like cells in drug resistance: A review of mechanisms and novel therapeutic strategies to overcome drug resistance</title>
		<author>
			<persName><forename type="first">T</forename><surname>Saha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Lukong</surname></persName>
		</author>
		<idno type="DOI">10.3389/fonc.2022.856974</idno>
		<ptr target="https://doi.org/10.3389/fonc.2022.856974" />
	</analytic>
	<monogr>
		<title level="j">Front. Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">856974</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The molecular machinery of regulated cell death</title>
		<author>
			<persName><forename type="first">D</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Vanden Berghe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Vandenabeele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kroemer</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41422-019-0164-5</idno>
		<idno>41422-019-0164-5</idno>
		<ptr target="https://doi.org/10.1038/s" />
	</analytic>
	<monogr>
		<title level="j">Cell Res</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="347" to="364" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Copper induces cell death by targeting lipoylated TCA cycle proteins</title>
		<author>
			<persName><forename type="first">P</forename><surname>Tsvetkov</surname></persName>
		</author>
		<idno type="DOI">10.1126/science.abf0529</idno>
		<ptr target="https://doi.org/10.1126/science.abf05" />
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page">29</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Serum copper and zinc levels in breast cancer: A meta-analysis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Feng</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jtemb.2020.126629</idno>
		<ptr target="https://doi.org/10.1016/j.jtemb.2020.126629" />
	</analytic>
	<monogr>
		<title level="j">J. Trace Elem. Med. Biol. Organ Soc. Miner. Trace Elem. (GMS)</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page">126629</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Serum copper level and the copper-to-zinc ratio could be useful in the prediction of lung cancer and its prognosis: A case-control study in Northeast China</title>
		<author>
			<persName><forename type="first">W</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1080/01635581.2020.1817957</idno>
		<ptr target="https://doi.org/" />
	</analytic>
	<monogr>
		<title level="j">Nutr. Cancer</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page">57</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Trace element and heavy metal levels in colorectal cancer: Comparison between cancerous and non-cancerous tissues</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sohrabi</surname></persName>
		</author>
		<idno type="DOI">10.1007/s12011-017-1099-7</idno>
		<idno>12011-017-1099-7</idno>
		<ptr target="https://doi.org/10.1007/s" />
	</analytic>
	<monogr>
		<title level="j">Biol. Trace Elem. Res</title>
		<imprint>
			<biblScope unit="volume">183</biblScope>
			<biblScope unit="page" from="1" to="8" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Changes in the serum levels of trace elements before and after the operation in thyroid cancer patients</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Baltaci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Dundar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Aksoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mogulkoc</surname></persName>
		</author>
		<idno type="DOI">10.1007/s12011-016-0768-2</idno>
		<ptr target="https://doi.org/10.1007/s12011-016-0768-2" />
	</analytic>
	<monogr>
		<title level="j">Biol. Trace Elem. Res</title>
		<imprint>
			<biblScope unit="volume">175</biblScope>
			<biblScope unit="page" from="57" to="64" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Serum levels of selenium, zinc, copper, manganese, and iron in prostate cancer patients</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A K</forename><surname>Saleh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Adly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Abdelkhaliq</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Nassir</surname></persName>
		</author>
		<idno type="DOI">10.1159/000499261</idno>
		<ptr target="https://doi.org/10.1159/00049" />
	</analytic>
	<monogr>
		<title level="j">Curr. Urol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">9261</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Copper in tumors and the use of copper-based compounds in cancer treatment</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Da Silva</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jinorgbio.2021.111634</idno>
		<ptr target="https://doi.org/10.1016/j.jinorgbio.2021.111634" />
	</analytic>
	<monogr>
		<title level="j">J. Inorg. Biochem</title>
		<imprint>
			<biblScope unit="volume">226</biblScope>
			<biblScope unit="page">111634</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">The cuproptosis-related signature predicts prognosis and indicates immune microenvironment in breast cancer</title>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.3389/fgene.2022.977322</idno>
		<ptr target="https://doi.org/10.3389/fgene.2022.977322" />
	</analytic>
	<monogr>
		<title level="j">Front. Genet</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">977322</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Identification of cuproptosis-related patterns and construction of a scoring system for predicting prognosis, tumor microenvironment-infiltration characteristics, and immunotherapy efficacy in breast cancer</title>
		<author>
			<persName><forename type="first">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pang</surname></persName>
		</author>
		<idno type="DOI">10.3389/fonc.2022.966511</idno>
		<ptr target="https://doi.org/10.3389/fonc.2022.966511" />
	</analytic>
	<monogr>
		<title level="j">Front. Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">966511</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Identification of cuproptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.3389/fimmu.2022.996836</idno>
		<ptr target="https://doi.org/10.3389/fimmu.2022.996836" />
	</analytic>
	<monogr>
		<title level="j">Front. Immunol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">996836</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Sha</surname></persName>
		</author>
		<idno type="DOI">10.3389/fimmu.2022.922780</idno>
		<ptr target="https://doi.org/10.3389/fimmu.2022.922780" />
	</analytic>
	<monogr>
		<title level="j">Front. Immunol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">922780</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Connecting copper and cancer: from transition metal signalling to metalloplasia</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Ge</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41568-021-00417-2</idno>
		<idno>41568-021-00417-2</idno>
		<ptr target="https://doi.org/10.1038/s" />
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Cancer</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="102" to="113" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Acquired resistance to HER2-targeted therapies creates vulnerability to ATP synthase inhibition</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gale</surname></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.can-18-3985</idno>
		<ptr target="https://doi.org/10.1158/0008-5472.can-18-3985" />
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="524" to="535" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response</title>
		<author>
			<persName><forename type="first">P</forename><surname>Jiang</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41591-018-0136-1</idno>
		<idno>41591-018-0136-1</idno>
		<ptr target="https://doi.org/10.1038/s" />
	</analytic>
	<monogr>
		<title level="j">Nat. Med</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1550" to="1558" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Molecular biology and biochemistry of pyruvate dehydrogenase complexes</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Roche</surname></persName>
		</author>
		<idno type="DOI">10.1096/fasebj.4.14.2227213</idno>
		<ptr target="https://doi.org/10.1096/fasebj.4.14.22272" />
	</analytic>
	<monogr>
		<title level="j">FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">13</biblScope>
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Crystal structure of pyruvate dehydrogenase kinase 3 bound to lipoyl domain 2 of human pyruvate dehydrogenase complex</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Chuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Tso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Wynn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Chuang</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.emboj.7600663</idno>
		<ptr target="https://doi.org/10.1038/sj.emboj" />
	</analytic>
	<monogr>
		<title level="j">EMBO J</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page">63</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Lipoic acid metabolism and mitochondrial redox regulation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Solmonson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Deberardinis</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.TM117.000259</idno>
		<ptr target="https://doi.org/10.1074/jbc" />
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">293</biblScope>
			<biblScope unit="page">259</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note>TM</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">DLAT subunit of the pyruvate dehydrogenase complex is upregulated in gastric cancer-implications in cancer therapy</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">Q</forename><surname>Goh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Ow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Kuznetsov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">P</forename><surname>Lim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am. J. Transl. Res</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1140" to="1151" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">A novel cuproptosis-related signature identified DLAT as a prognostic biomarker for hepatocellular carcinoma patients</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Bai</surname></persName>
		</author>
		<idno type="DOI">10.14740/wjon1529</idno>
		<ptr target="https://doi.org/10.14740/wjon" />
	</analytic>
	<monogr>
		<title level="j">World J. Oncol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">529</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Glycolysis-related gene dihydrolipoamide acetyltransferase promotes poor prognosis in hepatocellular carcinoma through the Wnt/β-catenin and PI3K/Akt signaling pathways</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhou</surname></persName>
		</author>
		<idno type="DOI">10.21037/atm-22-5272</idno>
		<ptr target="https://doi.org/10.21037/atm-22-5272" />
	</analytic>
	<monogr>
		<title level="j">Ann. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">1240</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">T</forename><surname>Junttila</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ccr.2009.03.020</idno>
		<ptr target="https://doi.org/10.1016/j.ccr.2009.03.020" />
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="429" to="440" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Molina</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="4744" to="4749" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Clynes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Towers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Presta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Ravetch</surname></persName>
		</author>
		<idno type="DOI">10.1038/74704</idno>
		<ptr target="https://doi.org/10.1038/74704" />
	</analytic>
	<monogr>
		<title level="j">Nat. Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="443" to="446" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism?</title>
		<author>
			<persName><forename type="first">L</forename><surname>Arnould</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.bjc.6602930</idno>
		<ptr target="https://doi.org/10.1038/sj.bjc" />
	</analytic>
	<monogr>
		<title level="j">Br. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page">30</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Emerging therapeutics for patients with triple-negative breast cancer</title>
		<author>
			<persName><forename type="first">E</forename><surname>Agostinetto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Eiger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Punie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>De Azambuja</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11912-021-01038-6</idno>
		<idno>11912-021-01038-6</idno>
		<ptr target="https://doi.org/10.1007/s" />
	</analytic>
	<monogr>
		<title level="j">Curr. Oncol. Rep</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page">57</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer</title>
		<author>
			<persName><forename type="first">E</forename><surname>Agostinetto</surname></persName>
		</author>
		<idno type="DOI">10.1080/13543784.2022.2049232</idno>
		<idno>1080/ 13543 784. 2022. 20492</idno>
		<ptr target="https://doi.org/10" />
	</analytic>
	<monogr>
		<title level="j">Expert Opin. Investig. Drugs</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page">32</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">The genomic landscape of breast cancer and its interaction with host immunity</title>
		<author>
			<persName><forename type="first">S</forename><surname>Luen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Virassamy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Savas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Salgado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Loi</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.breast.2016.07.015</idno>
		<ptr target="https://doi.org/10.1016/j.breast.2016.07.015" />
	</analytic>
	<monogr>
		<title level="j">Breast (Edinburgh, Scotland)</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="241" to="250" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art</title>
		<author>
			<persName><forename type="first">C</forename><surname>Solinas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Carbognin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>De Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Criscitiello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lambertini</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.breast.2017.07.005</idno>
		<ptr target="https://doi.org/10.1016/j.breast.2017.07.005" />
	</analytic>
	<monogr>
		<title level="j">Breast</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="142" to="150" />
			<date type="published" when="2017">2017</date>
			<pubPlace>Edinburgh, Scotland</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Rescue of TCA cycle dysfunction for cancer therapy</title>
		<author>
			<persName><forename type="first">J</forename><surname>Marquez</surname></persName>
		</author>
		<idno type="DOI">10.3390/jcm8122161</idno>
		<ptr target="https://doi.org/10.3390/jcm" />
	</analytic>
	<monogr>
		<title level="j">J. Clin. Med</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page">22161</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Reductive carboxylation supports growth in tumour cells with defective mitochondria</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Mullen</surname></persName>
		</author>
		<idno type="DOI">10.1038/nature10642</idno>
		<ptr target="https://doi.org/10.1038/nature10642" />
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">481</biblScope>
			<biblScope unit="page" from="385" to="388" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Clinical and genetic spectrum of pyruvate dehydrogenase deficiency: Dihydrolipoamide acetyltransferase (E2) deficiency</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Head</surname></persName>
		</author>
		<idno type="DOI">10.1002/ana.20550</idno>
		<ptr target="https://doi.org/10.1002/ana.20550" />
	</analytic>
	<monogr>
		<title level="j">Ann. Neurol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="234" to="241" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">ERN1 dependent impact of glutamine and glucose deprivations on the pyruvate dehydrogenase genes expression in glioma cells</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">O</forename><surname>Shatokhina</surname></persName>
		</author>
		<idno type="DOI">10.2478/enr-2022-0027</idno>
		<ptr target="https://doi.org/10.2478/enr-2022-0027" />
	</analytic>
	<monogr>
		<title level="j">Endocr. Regul</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="254" to="264" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">MUC1 triggers lineage plasticity of Her2 positive mammary tumors</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Pang</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41388-022-02320-y</idno>
		<ptr target="https://doi.org/10.1038/s41388-022-02320-y" />
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="3064" to="3078" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Metabolic pathways underlying GATA6 regulating Trastuzumab resistance in Gastric Cancer cells based on untargeted metabolomics</title>
		<author>
			<persName><forename type="first">J</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bhetuwal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Liu</surname></persName>
		</author>
		<idno type="DOI">10.7150/ijms.50563</idno>
		<ptr target="https://doi.org/10.7150/ijms.50563" />
	</analytic>
	<monogr>
		<title level="j">Int. J. Med. Sci</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="3146" to="3164" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">S</forename><surname>Lossos</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa032520</idno>
		<ptr target="https://doi.org/10.1056/" />
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">350</biblScope>
			<biblScope unit="page">20</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">limma powers differential expression analyses for RNA-sequencing and microarray studies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Ritchie</surname></persName>
		</author>
		<idno type="DOI">10.1093/nar/gkv007</idno>
		<ptr target="https://doi.org/10.1093/nar/gkv007" />
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page">47</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Recent advances in Lynch syndrome</title>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wu</surname></persName>
		</author>
		<idno type="DOI">10.1186/s40164-021-00231-4</idno>
		<idno>1186/ s40164-021- 00231-4</idno>
		<ptr target="https://doi.org/10" />
	</analytic>
	<monogr>
		<title level="j">Exp. Hematol. Oncol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">The immune landscape of cancer</title>
		<author>
			<persName><forename type="first">V</forename><surname>Thorsson</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.immuni.2018.03.023</idno>
		<ptr target="https://doi.org/10.1016/j.immuni.2018.03" />
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page">23</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Landscape of microsatellite instability across 39 cancer types</title>
		<author>
			<persName><forename type="first">R</forename><surname>Bonneville</surname></persName>
		</author>
		<idno type="DOI">10.1200/po.17.00073</idno>
		<ptr target="https://doi.org/10.1200/po.17.00073" />
	</analytic>
	<monogr>
		<title level="j">JCO Precis. Oncol</title>
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Integrative analysis of gene expression and DNA methylation through one-class logistic regression machine learning identifies stemness features in medulloblastoma</title>
		<author>
			<persName><forename type="first">H</forename><surname>Lian</surname></persName>
		</author>
		<idno type="DOI">10.1002/1878-0261.12557</idno>
		<ptr target="https://doi.org/10.1002/1878-0261.12557" />
	</analytic>
	<monogr>
		<title level="j">Mol. Oncol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="2227" to="2245" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Characterization of glycolysis-associated molecules in the tumor microenvironment revealed by pan-cancer tissues and lung cancer single cell data</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wei</surname></persName>
		</author>
		<idno type="DOI">10.3390/cancers12071788</idno>
		<ptr target="https://doi.org/10.3390/cancers" />
	</analytic>
	<monogr>
		<title level="j">Cancers</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page">71788</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients</title>
		<author>
			<persName><forename type="first">B</forename><surname>Gyorffy</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10549-009-0674-9</idno>
		<idno>10549-009-0674-9</idno>
		<ptr target="https://doi.org/10.1007/s" />
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res. Treat</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="725" to="731" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">com: A web tool for the comparison of gene expression in normal, tumor and metastatic tissues</title>
		<author>
			<persName><forename type="first">Á</forename><surname>Bartha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Győrffy</surname></persName>
		</author>
		<author>
			<persName><surname>Tnmplot</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms22052622</idno>
		<ptr target="https://doi.org/10.3390/ijms" />
	</analytic>
	<monogr>
		<title level="j">Int. J. Mol. Sci</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="20526" to="20548" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Kyoto encyclopedia of genes and genomes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kanehisa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Goto</surname></persName>
		</author>
		<author>
			<persName><surname>Kegg</surname></persName>
		</author>
		<idno type="DOI">10.1093/nar/28.1.27</idno>
		<ptr target="https://doi.org/10.1093/nar/28.1.27" />
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="27" to="30" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">KEGG for taxonomy-based analysis of pathways and genomes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kanehisa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Furumichi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kawashima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ishiguro-Watanabe</surname></persName>
		</author>
		<idno type="DOI">10.1093/nar/gkac963</idno>
		<ptr target="https://doi.org/10.1093/nar/gkac" />
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page">63</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Robust enumeration of cell subsets from tissue expression profiles</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Newman</surname></persName>
		</author>
		<idno type="DOI">10.1038/nmeth.3337</idno>
		<ptr target="https://doi.org/10.1038/nmeth.3337" />
	</analytic>
	<monogr>
		<title level="j">Nat. Methods</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="453" to="457" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures</title>
		<author>
			<persName><forename type="first">D</forename><surname>Zeng</surname></persName>
		</author>
		<idno type="DOI">10.1158/2326-6066.cir-18-0436</idno>
		<ptr target="https://doi.org/10.1158/2326-6066.cir-18-0436" />
	</analytic>
	<monogr>
		<title level="j">Cancer Immunol. Res</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="737" to="750" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
